Ajanta Pharma Limited (AJANTPHARM): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Ajanta Pharma Limited, explained in plain English.
- Ajanta Pharma Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- AJANTPHARM closed at ₹3,317.70 on 20 November 2026.
- Over the past year the shares are up 32.1%, trading between ₹2,465.00 and ₹3,796.00.
- Reported fundamentals show return on equity of 27.53%, a net margin of 20.31%, debt to equity of 3.17.
- Our Pulse grade checklist scores it A (81/100) across momentum, growth, profitability and safety on fixed thresholds.
- Annualised volatility over the past year is 25.88% with a maximum drawdown of -13.16% and a beta of 0.43 against NIFTY 50.
Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma, Biocon
Last traded values from 20 Nov 2026. Closed — weekend.
Pharma & Healthcare
Ajanta Pharmaceuticals (AJANTPHARM)
₹3,283.9
▲ 13.6 (+0.42%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Weak momentum · 1/51M
-0.45%
3M
-10.24%
6M
+2.98%
1Y
+30.80%
Where it sits in its 52-week range
65%Below 52-week high
11.7%
32.1% above the low
Momentum read
Weak
1/5 checks passed
52-wk high
₹3,718.2
52-wk low
₹2,485.7
Market cap
—
P/E (trailing)
—
Dividend yield
—
ROE
—
Profit margin
—
Revenue growth
—
Price / Book
—
Debt / Equity
—
EPS (TTM)
—
Book value
—
Beta
0.43
Pulse grade: F, 22 out of 100
Momentum
F- ✕Trading above 50-day average
- ✓Trading above 200-day average
- ✕RSI in healthy 45-70 zone
- ✕Positive 3-month return
Growth
D- ✕Revenue growth above 12%
- ✕Revenue growing above 5%
- ✓Quarterly profits trending up
Profitability
F- ✕Return on equity above 18%
- ✕Return on equity above 12%
- ✕Profit margin above 12%
Safety
F- ✕Debt below 50
- ✕Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹1,794 crore · net profit ₹388 crore · margin 21.6%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
AJANTPHARM headlines
No AJANTPHARM stories right now.
AJANTPHARM filings & announcements
AJANTPHARM, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
25.85%
Sharpe ratio
0.93
Sortino ratio
1.46
Max drawdown
-13.16%
Daily VaR (95%)
-2.49%
CAGR (1Y)
30.94%
Return skew
0.6
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.